(1995). A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut
(2005). A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol
(2010). AA: Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohorts. Inflamm Bowel Dis
(2008). Bodegraven AA: Histopathology of liver biopsies from a thiopurine-naive inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia.
(2006). CJ: 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent? J Hepatol
(2008). CJ: Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig Liver Dis
(2007). CJ: Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol
(2003). CJ: Safety of thiopurines in the treatment of inflammatory bowel disease.
(2006). CT: Transforming growth factorbeta induces development of the T(H)17 lineage. Nature
(2002). DP: The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut
(2003). et al: CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.
(2000). et al: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology
(2007). et al: Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut
(1986). et al: Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA
(2008). Further experience with the use of 6-thioguanine in patients with Crohn’s disease. Inflamm Bowel Dis
(2003). Hohler T: Veno-occlusive disease (VOD) in Crohn’s disease (CD) treated with azathioprine. Dig Dis Sci
(2004). Hommes DW, Hooymans PM: Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit
(2001). Inflammation location, but not type, determines the increase in
(2006). Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature
(2007). LG: Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? Dig Liver Dis
(1993). Lilleyman JS: Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child
(2007). Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis
(2005). LJ: Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther
(1995). LR: Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med
(2008). Morel F: Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol In Vitro
(2007). O’Morain C: Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease.
(2005). On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients.
(1980). Pasternack BS: Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study.
(1998). Rees EP: Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by
(2005). Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.
(1993). Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest
(2003). Stange EF: Remission maintenance by tioguanine in chronic active Crohn’s disease. Aliment Pharmacol Ther
(2003). Targan SR, Poordad FF: 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology
(2002). Targan SR, Vasiliauskas EA: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology
(2004). Targan SR: Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol
(2011). Tlaskalova-Hogenova H: Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition. Clin Exp Immunol
(2003). W: High variation of tioguanine absorption in patients with chronic active Crohn’s disease. Aliment Pharmacol Ther